German biotech firm CureVac's COVID-19 vaccine records only 48 percent efficacy in the last-stage trial.

CureVac disclosed that its COVID-19 vaccine has an efficacy of 48 percent against fifteen COVID-19 variants.

CureVac disclosed that its COVID-19 vaccine has an efficacy of 48 percent against fifteen COVID-19 variants. CureVac published a press release on June 30, 2021, stating the results of their recent analysis from the Phase 2b/3 investigation. The study was conducted in 10 countries with fast-changing variant environments. The study looked at 40,000 patients to understand its vaccine efficacy. CVnCoV revealed an overall vaccine efficacy of 48 percent (83 vaccinations vs. 145 placeboes) against COVID-19 disease of any severity, including single non-respiratory mild symptoms, in the unusual setting of 15 strains circulating within the study population at the time of final analysis.

Further, the company said that the CureVac vaccination performed slightly better for younger volunteers: effectiveness improved to 53 percent for those aged 18 to 60. According to the researchers, the vaccine also gave 100 percent protection against hospitalization and death in that group.

According to Reuters and The New York Times, in clinical studies, the Moderna and Pfizer-BioNTech vaccines, which use the same mRNA technology as CureVac, achieved effectiveness rates of around 95 percent. According to Franz-Werner Haas, CureVac's CEO, the European Medicines Agency began a rolling study of CureVac's vaccine in February 2021. The corporation stated that it would continue to submit those documents. Vaccinations are critical in combating the COVID-19 pandemic and the proliferation of dynamic variants.